MoBiT
MoBiT:
Three leading products BAB-05, BAB-09 and BAB-0120 are in late preclinical stage. Outstanding efficacies and safety profiles have been demonstrated in rodents and NHP. IND application is expected in Q2/2026 (BAB-05) and Q4/2026 (BAB-09), respectively.
- Long-acting monovalent BiTE targeting CD3 and CD19 with high specificity
- High production yield in stable CHO expression system
- High homogeneity and stability, similar to those of mAbs, suitable for dosing subcutaneously
- T cell-dependent cytotoxicity toward CD19+ cells
- Optimal cytokine release profile due to moderate T cell activation
- Effectively deplete B cells and activate T cells in NHPs
- Broad indications of B-cell hematological tumors and B-cell autoimmune diseases
- Long-acting monovalent BiTE targeting CD3 and PSMA with high specificity
- High production yield in stable CHO expression system
- High homogeneity and stability
- T cell-dependent cytotoxicity toward PSMA+ cells
- Optimal cytokine release profile due to moderate T cell activation
- Indication: castrate resistant prostate cancer
- Long-acting monovalentbispecific antibody targeting EGFR and cMet
- High production yield in stable CHO expression system
- High homogeneity and stability
- Inhibit downstream phosphorylation signal of EGFR and cMet
- Optimal affinity profile on each target
- Synergize with TKI to overcome resistance issues